Can a simple pill shield transplant patients from deadly fungal infections?
NCT ID NCT04725942
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether the drug posaconazole can prevent fungal lung infections in people who have had a stem cell transplant. 360 patients took the drug for 90 days after their transplant. Researchers checked drug levels in the blood and tracked how many patients got infections. The goal was to find the right dose to keep patients safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
posaconazole tablets
What this could lead to
If successful, this could confirm that posaconazole is a safe and effective way to prevent serious fungal lung infections in stem cell transplant patients.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. The drug may not prevent all infections and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
-
Shanxi Bethune Hospital
Taiyuan, China
-
The Second Hospital of Hebei Medical University
Shijia Zhuang, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China